QTREX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Requirement

QTREX faces Nasdaq delisting risk but has six days above the $1.00 threshold.

What the company is saying

QTREX Quantum Ltd. reports that it received a written notice from Nasdaq on October 5, 2026, for failing to maintain the minimum $1.00 per share closing bid price over 30 consecutive business days from August 20 to October 1, 2026. The company emphasizes that this notification does not immediately affect its listing or trading status, and shares continue to trade under the symbol QTEX. Management highlights that since October 2, 2026, the closing bid price has exceeded $1.00 for six consecutive business days, suggesting a recent improvement. The company outlines the compliance process: if the share price remains at or above $1.00 for 10 consecutive business days before April 3, 2027, Nasdaq will confirm compliance. The announcement briefly references ongoing development in quantum computing infrastructure, AME applications, and medical technology, but does not provide operational or financial milestones for these initiatives. The tone is factual and procedural, focusing on regulatory compliance rather than business performance.

What the data suggests

The company was non-compliant with Nasdaq’s $1.00 minimum bid price requirement for 30 consecutive business days, triggering the October 5, 2026 notification. Since October 2, 2026, the stock has closed above $1.00 for six consecutive business days, but needs four more to meet the 10-day compliance threshold. The compliance window extends 180 calendar days from the notification, ending April 3, 2027. If compliance is achieved, Nasdaq will issue written confirmation and close the matter. No financial, operational, or transactional data are disclosed beyond the compliance timeline and share price thresholds. The announcement provides no evidence of progress or revenue from the company’s stated technology and medical business lines. The only hard facts are regulatory: share price history, compliance deadlines, and procedural next steps.

Analysis

The announcement is a factual compliance update regarding QTREX Quantum Ltd.'s Nasdaq listing status, triggered by a period of sub-$1.00 share price. All key compliance-related claims are supported by specific dates and thresholds, with no promotional or exaggerated language. The brief business overview mentions ongoing development and monetization efforts but provides no operational, financial, or milestone evidence for these activities, and does not attempt to overstate progress or imminent benefits. The forward-looking statements are limited to regulatory compliance mechanics and generic business development language, with no inflated projections or promises. There is no mention of large capital outlays or claims of transformative near-term impact. The tone is proportionate to the facts disclosed.

Risk flags

• ●QTREX remains at risk of Nasdaq delisting if it fails to maintain a closing bid price of at least $1.00 for 10 consecutive business days before April 3, 2027; delisting would reduce liquidity and access to capital markets.
• ●The company’s announcement provides no operational or financial performance data, leaving investors without insight into underlying business health or progress in its technology and medical portfolios.
• ●Recent share price recovery above $1.00 has lasted only six days, so compliance is not yet secured; any reversal could reset the compliance clock and prolong regulatory uncertainty.

Bottom line

QTREX Quantum Ltd. is under Nasdaq scrutiny after its shares traded below $1.00 for 30 straight business days, but has since posted six consecutive days above the threshold. The company must sustain this level for four more business days to resolve the compliance issue, with a final deadline of April 3, 2027. No new information is provided about the company’s operational or financial performance, so the announcement is purely procedural. The most immediate factor for investors is whether the share price remains above $1.00 long enough to satisfy Nasdaq’s 10-day rule. Until compliance is confirmed, the risk of delisting and its consequences for liquidity and capital access remain. Investors should focus on the daily share price and await further updates on both regulatory status and substantive business progress.

Announcement summary

(NASDAQ:QTEX) QTREX Quantum Ltd. announced that on October 5, 2026, it received a written notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that, for the 30 consecutive business days from August 20, 2026 through October 1, 2026, the closing bid price of the Company’s ordinary shares had been below the minimum of $1.00 per share required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The notification does not have any immediate effect on the listing or trading of the Company’s ordinary shares, which continue to be listed and traded on The Nasdaq Capital Market under the symbol “QTEX”. Since the end of the measurement period, the closing bid price of the Company’s ordinary shares has been above $1.00 per share on each of the 6 consecutive business days from October 2, 2026 through October 9, 2026. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided a period of 180 calendar days from the date of the notification, or until April 3, 2027, to regain compliance with the minimum bid price requirement. If at any time during this period the closing bid price of the Company’s ordinary shares is at least $1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide the Company with written confirmation of compliance and the matter will be closed. QTREX Quantum Ltd. is focused on advancing Additively Manufactured Electronics (AME) for quantum computing infrastructure. Following its acquisition of the AME platform, the Company is developing high-density, thermally optimized quantum connectivity solutions for dilution cryostats and advancing AME applications for defense, aerospace, missile, space, and other mission-critical environments. The Company also continues to advance its medical technology portfolio, including respiratory support and blood monitoring platforms, while actively working to monetize certain parts of the medical business.

Disagree with this article?